Page 75 - Aet News Today

Pfizer’s new FDA-approved ulcerative colitis drug Velsipity comes from its $6.7 billion Arena Pharmaceuticals acquisition. The small molecule will compete against blockbuster Bristol Myers Squibb drug Zeposia, which addresses the same target.

At HLTH, General Catalyst Principal Candace Richardson discussed some of the questions she frequently asks startups during investment meetings. Some of these include "Do you stratify your outcomes data by different populations to ensure your model works well for everyone?" and "Is serving Medicaid populations on your roadmap?"

Cancer and pharmacy services are driving up costs for employers. One Mercer exec recently laid out several recommendations for employers to manage these costs.

BioNTech gains rights to a MediLink Therapeutics antibody drug conjugate that targets tumors expressing the HER3 protein. The deal comes six months after the German company entered the ADC field by acquiring rights to two therapeutic candidates from DualityBio.

At HLTH, Bessemer investors Sofia Guerra and Steve Kraus detailed four predictions about where they think the digital health world is headed in 2024. One of these was that "services-as-software" will emerge as a new category of healthcare AI. Another was that some healthcare technology vendors will have to rethink their distribution models and rely on indirect monetization strategies.

Afentra plc (LON:AET – Get Free Report)’s stock price rose 2.5% during mid-day trading on Tuesday . The stock traded as high as GBX 27.28 ($0.33) and last traded at GBX 26.65 ($0.33). Approximately 704,206 shares traded hands during trading, a decline of 27% from the average daily volume of 963,342 shares. The stock had […]

Walmart's relationship with Included Health dates back to 2016 when its previous incarnation - Doctor on Demand - began providing virtual urgent care services to Walmart employees in three states. Nearly eight years later, the San Francisco company continues to be the only partner charged with delivering virtual primary care to almost 1 million people in 49 states.

European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.

In this episode, we discuss SCAN Health Plan's recent launch of SCAN Inspired, a Medicare Advantage plan designed for women.

Noom is now offering Noom Med to employers. The program is intended for patients who need more clinical support in their weight loss journey. It offers access to a clinician and medications, including GLP-1s.